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Significance of Pathophysiology
Malignant Hyperthermia
Leonid Levertov, BSN-RN, CCRN
Introduction
Providing patient care in the 
operating room as a nurse anesthetist is 
rewarding and challenging. There is a 
paramount level of responsibility that 
lies on certified registered nurse 
anesthetist (CRNA). Recognition of 
serious life threatening conditions by 
CRNA must be prompt and treated 
urgently. As a student registered nurse 
anesthetist and future CRNA, knowing 
how to recognize and treat developed 
emergency conditions while patient is 
under anesthesia or recovering from 
anesthesia is an absolute requirement.                     
Malignant hyperthermia (MH), is a rare 
autosomal dominant hypermetabolic 
“potentially fatal disorder of skeletal 
muscles” (Riazi, & Brandom, 2015). 
Malignant hyperthermia is caused by 
volatile anesthetics (desflurane, 
sevoflurane, isoflurane) or depolarizing 
muscle relaxant (succinylcholine). 
Incidence of MH varies between 
1/50,000 to 1/250,000 and highest in 
young population with average age of 
18.3 years upon exposure to volatile 
anesthetics or succinylcholine and is 
associated with 23 genetic mutations 
(Nagelhout & Plaus, 2014).
In contrast, according to Malignant 
Hyperthermia Association of United 
States (MHAUS, 2015) MH arises 
1/100,000 in adults and 1/30,000 in 
children during exposure to triggering 
agent. Mitchell-Brown (2012) reports 
that there are more than 80 genetic 
defects associated with MH. The two 
gene mutations directly associated with 
MH susceptibility are RYR1 and 
CACNA1S (Rosenberg, Pollock, 
Schiemann, Bulger, & Stowell, 2015).  
However, another study states that only 
1% of MH cases due to CACNA1S gene 
on chromosome 1q32, and MH 
susceptibility due to mutation of the 
RYR1 gene found on chromosome 
19q13.1 (Salazar, Yang, Shen, Abdullah, 
& Kim, 2014). Wisconsin, Nebraska, 
West Virginia, and Michigan are states 
with most MH occurrences. MH has 
higher prevalence among men versus 
women, even though it is autosomal 
dominant disorder.
Upon exposure, MH susceptible 
individuals could progress to potentially 
fatal hypermetabolic crisis which occurs 
shortly after induction of anesthesia 
(Cain, Riess, Gettrust, & Novalija, 2014). 
MH is known to happen in post 
anesthesia care unit (PACU) or any
Signs and Symptoms
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Pathophysiology
location where patient is recovering 
from general anesthesia during which 
volatile anesthetics or succinylcholine 
were used (Cain et al., 2014). MH could 
also be triggered by stressors alone such 
as excessive exercise and heat 
(Rosenberg et al., 2015). In order to 
provide lifesaving intervention for 
patient who is experiencing MH, it is 
imperative to understand 
pathophysiology, signs and symptoms, 
management and treatment, and the 
importance of thorough preoperative 
patient assessment for prevention of MH 
occurrence (Nagelhout & Plaus, 2014). 
Untreated MH could lead to multiple 
organ failure and death (Seifert, Wahr, 
Pace, Cochrane, & Bagnola, 2014). 
-At first suspicion of MH, discontinue inhalation agent, call MH hotline
-Hyperventilate with 100% oxygen at high flows (10L/min) to improve
tissue oxygenation, eliminate CO2. 
-Administer dantrolene 2.5mg/kg IV bolus and repeat as necessary every 5-
10 minutes until symptoms subside. If total dose greater than 20 mg/kg of
dantrolene administered without improvement, reconsider diagnosis. 20
-mg vial of dantrolene must be reconstituted with 60 ml of sterile water for
injection. Additional medical personnel must be utilized to reconstitute
dantrolene with sterile water, since it is time consuming. 
-Initiate cooling by lavage, chilled IV normal saline, surface cooling.
Patient’s temperature should be kept under 38.5ºC (Bandschapp & Girard,
2012)
-Do not administer calcium channel blockers with dantrolene. 
-Obtain ABG, electrolytes, glucose every 15 minutes. Correct metabolic
acidosis with sodium bicarbonate 1-2 meq/kg, based on pH and base  
deficit. -Obtaine coagulation profile, CK, blood and urine myoglobin, liver
enzyme levels. 
-Treat hyperkalemia with hyperventilation, bicarbonate and intravenous
insulin and glucose. 
-Maintain urine output greater than 2ml/kg/hr with hydration, lasix (0.5-1
mg/kg) and mannitol as needed. Invasive hemodynamic monitoring should
be established (Nagelhout & Plaus, 2014). 
Otterbein University, Westerville, Ohio
Ryanodex, a new dantrolene formulation. (2016). Retrieved from: 
http://www.slideshare.net/merdonius1/ryanodexa-new-
dantrolene-formulation 
Conclusion
Implications for Nursing Care
Schneiderbanger, Johannsen, Roewer, & Schuster, 
2014. 
MH is rare but potentially fatal skeletal muscle disorder which requires prompt 
intervention to decrease mortality rate. In the initial years of MH discovery, mortality rate 
due to MH disorder was 80%. In recent years, this number has changed to approximately 
5%, and is contributed to increased education and awareness among healthcare providers, 
early recognition and prompt administration of dantrolene sodium to stop MH crisis 
(Mitchell-Brown, 2012). Dantrolene inhibits calcium release by inhibiting RYR receptor at 
postsynaptic dendrite (Bandschapp & Gerard, 2012). Multiple shared signs and symptoms 
with other disorders, variable penetrance and absence of phenotypical characteristics in 
the absence of triggering agent and variable onset after administration of triggering agent 
makes it difficult to timely identify MH crisis and implement timely intervention. 
Understanding pathophysiology of MH could lead to early recognition and intervention 
and better outcomes for patients experiencing MH crisis.
-Variable onset of one to 36 hours of 
administration of volatile anesthetic or 
succinylcholine (Mitchell-Brown, 2012). 
-Early clinical signs:
Hypercapnia, with rise in EtCO2
with normal patient ventilation (indicating 
underlying hypermetabolism) and 
increased end-tidal carbon dioxide 
(ETCO2) refractory to increased 
ventilation or additional administration of 
anesthetic
Masseter muscle spasm
Tachycardia without explanation 
(Seifert et al., 2014). 
-Cardinal symptoms: rigidity, muscle 
breakdown (rhabdomyolysis; causing 
increase CK and myoglobin), respiratory 
acidosis, temperature increase, cardiac 
involvement, and “other indicators of 
metabolic derangement not part of a single 
process” (Heytens, Forget, Scholtès, & 
Veyckemans, 2015). 
Labile blood pressures, skim mottling,
cyanosis. 
-Late clinical signs: Hyperthermia
body core temperature may rise at a rate 
of 1ºC to 2ºC every 5 minutes with average 
of 39.3ºC or 102.7ºF, with temperature 
rising above 43.3 ºC (110ºF). 
Acidosis, hyperkalemia and hyperthermia 
causes cardiac irritability, arrhythmias and 
could lead to cardiac arrest. Death from 
MH is typically due to cardiovascular 
collapse (Mitchell-Brown, 2012).  
Laboratory results typically show 
byproducts of muscle breakdown such as 
myoglobinuria (dark colored urine), 
hyperkalemia, and elevated creatinine 
kinase level. Arterial blood gas shows 
mixed metabolic and respiratory acidosis.
Shresta, 2013
The RYR1-ryanodine receptor controls 
calcium release from sarcoplasmic 
reticulum (skeletal muscle) and is one of the 
main defects for MH susceptible individuals, 
however 40-50% of MH susceptible 
individuals have no associated defect in 
RYR1 receptor (Riazi, & Brandom, 2015). 
MH susceptibility linked to calcium release 
defect in skeletal muscle; no established 
linkage to calcium release flaw in cardiac or 
smooth muscle cells (Mitchell-Brown, 2012). 
In MH susceptible patients, volatile 
anesthetics and/or depolarizing muscle 
relaxant causes a defect in calcium 
regulation, leading to increased myoplasmic
calcium levels. Excess calcium release 
causes uncoupling of oxidative 
phosphorylation and increased metabolic 
rate (Marino & Sutin, 2014). Excess 
myoplasmic calcium levels cause sustained 
actin-myosin interaction (muscle 
contraction) which causes muscle rigidity, 
increased body temperature, increased 
production of carbon dioxide, and increased 
oxygen consumption (Riazi, & Brandom, 
2015). ATP dependent calcium reuptake 
mechanism attempts to stabilize calcium 
levels in myoplasm, thus increasing muscle 
metabolism. Accelerated cellular 
metabolism requires increased oxygen 
uptake and causes increased carbon dioxide 
level, heat production while using all 
available ATP, causing elevated lactic acid. 
Acidosis, hypethermia and ATP depletion 
leads to sarcolemma damage. Elevated 
levels of potassium (due to cell death and 
released potassium from the cell into blood 
stream), myoglobin (rhabdomyolysis, due to 
death of muscle cells), and creatinine kinase 
secreted into extracellular fluid (Nagelhout
& Plaus, 2014).  Elevated potassium levels, 
above 6 meq/L may lead to fatal 
dysrhythmias; myglobin released into 
bloodstream causes precipitate formation in 
renal tubules, leading to acute kidney injury 
(Mitchell-Brown, 2012). If no intervention 
implemented to stop excess calcium release, 
MH progression leads to left ventricular 
dysfunction due to hypertension, pulmonary 
edema and disseminated intravascular 
coagulation (DIC) (Mitchell-Brown, 2012). 
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Malignant hyperthermia is a rare, autosomal dominant disorder and 
medical emergency that requires immediate recognition and treatment 
in order to increase patient’s chances of survival. It has variable 
penetrance and is typically triggered by volatile anesthetics and/or 
depolarizing muscle relaxant (succinylcholine). CRNAs must perform a 
very thorough pre-operative assessment to detect any indications of 
patient’s MH susceptibility. Operating room personnel must be familiar 
with signs and symptoms of MH, especially early signs of MH in order to 
implement timely MH protocol treatment. CRNAs, operating room 
nurses and ICU nurses must be educated on MH treatment and 
management for best possible patient outcome. 
Please Call MH Hotline at:
1-800-644-9737 
Be prepared to give your name, number, facility and
email, in the event the call is dropped
(outside of the US: 209-417-3722 ) and
view our Managing an MH Crisis Page. (MHAUS, 2015)
